MBX Biosciences Inc (MBX)

NASD · Healthcare · Biotechnology · USA

MBX Biosciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders. Its proprietary PEP platform creates peptides with extended action profiles and low peak-to-trough ratios. Its pipeline includes canvuparatide for chronic hypoparathyroidism, obesity candidates, and imapextide for post-bariatric hypoglycemia.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the MBX Biosciences Inc stock.

Our verdict on MBX

Not valued: We cannot value this company yet.

ETFs with the most weight in MBX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than MBX in Biotechnology

129 more in this industry show a wider margin of safety.

Is MBX undervalued or overvalued?

We do not publish a verdict on MBX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of MBX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.